Replies to post #217207 on Biotech Values

[DewDiligence]

Mavyret scripts continue ramp-up:

• ABBV/ENTA’s HCV-new-patient share=39.2% in week ending 2/9/18, up from 35.2% in the prior week (according to IMS).

• ABBV/ENTA’s HCV-total-patient-share=34.2% in week ending 2/9/18, up from 29.6% in the prior week (according to IMS).

• Both NRx=39.2% and TRx=35.2% are the highest-ever weekly figures reported by IMS for ABBV/ENTA’s HCV share.